Next Article in Journal
Yeast Chromatin Mutants Reveal Altered mtDNA Copy Number and Impaired Mitochondrial Membrane Potential
Next Article in Special Issue
Fungal–Bacterial Co-Infections and Super-Infections among Hospitalized COVID-19 Patients: A Systematic Review
Previous Article in Journal
Successful Multimodal Therapy with Intracerebral Liposomal Amphotericin B and Systemic High-Dose Isavuconazole in Proven Disseminated Aspergillosis
Previous Article in Special Issue
Studying Fungal-Bacterial Relationships in the Human Gut Using an In Vitro Model (TIM-2)
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JoF
Volume 9
Issue 3
10.3390/jof9030328
jof-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

In Search for Reasons behind Helicobacter pylori Eradication Failure–Assessment of the Antibiotics Resistance Rate and Co-Existence of Helicobacter pylori with Candida Species

by
Ana Bačić
1,†,
Vladimir Milivojević
2,3,*,†,
Isidora Petković
1,
Dušan Kekić
3,4,
Ina Gajić
3,4,
Branislava Medić Brkić
3,5,
Dušan Popadić
3,4,
Tomica Milosavljević
6 and
Mirjana Rajilić-Stojanović
1
1
Department of Biochemical Engineering and Biotechnology, Faculty of Technology and Metallurgy, University of Belgrade, Karnegijeva 4, 11000 Belgrade, Serbia
2
Clinic for Gastroenterology and Hepatology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia
3
Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia
4
Institute for Microbiology and Immunology, Medical Faculty, University of Belgrade, 11000 Belgrade, Serbia
5
Institute for Pharmacology, Clinical Pharmacology and Toxicology, Medical Faculty University of Belgrade, 11000 Belgrade, Serbia
6
Euromedic General Hospital, 11000 Belgrade, Serbia
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
J. Fungi 2023, 9(3), 328; https://doi.org/10.3390/jof9030328
Submission received: 21 January 2023 / Revised: 24 February 2023 / Accepted: 1 March 2023 / Published: 7 March 2023
(This article belongs to the Special Issue Fungal-Bacterial Interactions: Importance for Health and Disease)
Browse Figures
Versions Notes

Abstract

:
Helicobacter pylori eradication is characterized by decreasing successful eradication rates. Although treatment failure is primarily associated with resistance to antibiotics, other unknown factors may influence the eradication outcome. This study aimed to assess the presence of the antibiotics resistance genes in H. pylori and the presence of Candida spp., which are proposed to be endosymbiotic hosts of H. pylori, in gastric biopsies of H. pylori-positive patients while simultaneously assessing their relationship. The detection and identification of Candida yeasts and the detection of mutations specific for clarithromycin and fluoroquinolones were performed by using the real-time PCR (RT-PCR) method on DNA extracted from 110 gastric biopsy samples of H. pylori-positive participants. Resistance rate to clarithromycin and fluoroquinolone was 52% and 47%, respectively. Antibiotic resistance was associated with more eradication attempts (p < 0.05). Candida species were detected in nine (8.18%) patients. Candida presence was associated with older age (p < 0.05). A high rate of antibiotic resistance was observed, while Candida presence was scarce, suggesting that endosymbiosis between H. pylori and Candida may not be a major contributing factor to the eradication failure. However, the older age favored Candida gastric mucosa colonization, which could contribute to gastric pathologies and microbiome dysbiosis.

1. Introduction

Helicobacter pylori is a Gram-negative, microaerophilic flagellated bacterium which is highly adjusted to the generally unfavorable conditions for microbial growth present in the human stomach. H. pylori is embedded in the gastric mucosa, where it locally adjusts the pH to a neutral value due to urease activity [1,2]. It is estimated that nearly 50% of the human population carries H. pylori in the stomach, with colonization prevalence ranging from 35% in developed countries to a strikingly high prevalence of 80% in some developing countries [3,4]. Although around 70% of the H. pylori carriers remain asymptomatic, H. pylori colonization is associated with several gastric pathologies, including gastritis, peptic ulcers, non-cardiac gastric adenocarcinoma and gastric mucosa-associated lymphoid tissue (MALT) lymphoma [1,5]. Today, H. pylori is recognized as a type 1 carcinogenic agent, responsible for ~90% of gastric cancer cases [1,6].
Confirmed infection with H. pylori is treated with antibiotics, and according to the WHO Global guidelines, triple therapy, comprising of clarithromycin, amoxicillin and a proton-pump inhibitor (PPI) is the most commonly used first-line treatment for the eradication of H. pylori in low-resistance regions, but according to new Maastrich VI guideline treatment with PPI-clarithromycin-containing triple therapy without prior susceptibility testing should be abandoned when the clarithromycin resistance rate in the region is more than 15% [7,8]. Data from the European Registry reveals that only quadruple therapies lasting at least 10 days are able to achieve over 90% eradication rates [9]. The data for second line treatment revealed that empiric second-line regimens including 14-day quinolone triple therapies, 14-day levofloxacin–bismuth quadruple therapy, 14-day tetracycline–bismuth classic quadruple therapy and 10-day bismuth quadruple therapy (as a single capsule) provided optimal effectiveness [10]. However, the worldwide increase in the prevalence of antibiotic-resistant H. pylori strains has compromised the effectiveness of antibiotic therapy and decreased the rate of successful eradication, with the alarming increase of multidrug-resistant H. pylori strains [8,11,12,13]. Recently published data on antimicrobial susceptibility of H. pylori from multiple centers across the USA and Europe, revealed an alarmingly high rate of clarithromycin resistance with a rate >15% in every region of the USA [14].
In addition to antibiotic resistance, H. pylori eradication success is also influenced by a number of other factors. It is well established that PPIs enhance the effect of antibiotics by increasing the gastric pH and ultimately H. pylori eradication. Their effect is under influence of the drug-metabolizing enzyme CYP2C19 and its gene polymorphism [15]. Moreover, several other mechanisms for the H. pylori resistance to the applied antibiotic therapy were proposed. Studies have shown that bacteria upon establishing certain cell density have the ability to produce extracellular substances, allowing them to form a biofilm. Biofilm provides a self-protective matrix that can make the bacteria up to 1000 times more resistant to antibiotics, and this mechanism could also potentially contribute to the failure of H. pylori eradication efforts [16]. Furthermore, it has recently been shown that H. pylori behaves as a facultative intracellular bacterium, found inside eukaryotic cells including human gastric epithelial cells, and macrophages and dendritic immune cells [17,18]. Interestingly, the presence of H. pylori inside the Candida yeasts’ vacuoles has been confirmed recently by fluorescence microscopy and H. pylori-specific genes and proteins have been isolated from the yeast cells [17,18,19,20]. Internalization of the H. pylori inside the Candida yeast cells has been characterized as a protective adaptation to stressful conditions, including changes in pH values, antibiotics treatments, and nutrient-deficient environment [16,21,22,23]. This endosymbiotic relationship has been demonstrated in samples from various body sites, including oral, gastric, and vaginal samples and different food sources [17]. In contrast to H. pylori, Candida cells are resistant to environmental stress and can survive temperatures above 40 °C and a pH in the range between 2 and 10 [16,17,18,19]. Several studies have shown that Candida colonization of the gastric mucosa is associated with several gastric pathologies. Moreover, the co-existence of Candida species and H. pylori has been confirmed in several studies and a synergistic relationship between these two microorganisms in the pathogenesis of gastric diseases has been suggested [16,24]. Based on this long-standing relationship between the presence of Candida and H. pylori, we hypothesized that Candida presence in the gastric compartment could contribute not only to H. pylori pathologies but also to the resistance to the applied antibiotic therapy.
For a long time, H. pylori has been considered the only true inhabitant of the human stomach. However, despite the harsh environmental conditions, the existence of a thriving and dynamic gastric microbial community has been proven [24,25,26,27]. It is estimated that the stomach is inhabited by 102–104 colony-forming units (CFU)/mL [28]. In addition to the bacterial communities, members of the fungal microbiota have also been identified in gastric biopsy samples, in the range of 0–102 CFU/mL [24,25,28]. Candida represents the most frequently isolated genus of yeasts, with C. albicans as the most frequently identified species [16,21,29]. As previously mentioned, we hypothetitzed that endosymbiosis between Candida and H. pylori could facilitate the H. pylori resistance to eradication treatment, as Candida yeasts could serve as reservoirs for an easier transmission [16]. In this setting, a high prevalence of Candida infection might contribute to an increase in H. pylori infection rates and might contribute to the challenges of its eradication.
To test the hypothesis in the present study we used molecular methods to test the frequency of concurrent infections with H. pylori and Candida fungi on a cohort of 110 H. pylori-positive patients. In addition to Candida detection and species level identification, any possible relationship between Candida presence in different histopathological categories of biopsies, demographic characteristics of patients, number of eradications and the type of antibiotic resistance mutation detected in H. pylori strains, was assessed.

2. Material and Methods

2.1. Patients

A total of 123 patients with symptoms of dyspepsia recruited at the University Clinical Centre of Serbia were enrolled in the study. During gastroscopy, gastric tissue biopsy samples from the patients’ stomach antrum, angular incisura and corpus were obtained according to the updated Sydney classification of gastritis [30]. The gastric samples were collected between September 2019 and 2021. The H. pylori-positive test was the inclusion criteria for the study. Demographic and clinical data of H. pylori-positive patients were recorded. Histological examinations were carried out in the Department of Pathohistology of the University Clinical Centre of Serbia. A semi-quantitative categorization of histopathological findings was performed and atrophy, inflammation and cellularity scores were assessed.

2.2. Ethical Statement

The study was approved by the Ethics Committee of the University Clinical Centre of Serbia (number 788/11). All patients were informed regarding the aim of the study and provided written informed consent in accordance with the World Medical Association Declaration of Helsinki.

2.3. DNA Extraction

Isolation of DNA from biopsies of the gastric mucosa was performed using the commercial kit, QIAmp DNA Mini (Qiagen, Hilden, Germany), according to the manufacturer’s instructions.

2.4. H. pylori Detection and Resistance

H. pylori was detected using the Giemsa stain (Giemsa’s stain solution of Muto Pure Chemicals Co., Ltd., Tokyo, Japan) on the mucosal surface during the histology examination and by molecular testing. The presence of mutations in genes related to antibiotic resistance was detected for the following genes involved in the H. pylori resistance mechanisms: 23S, gyrA, gyr87 and gyr91.
Molecular detection of H. pylori and resistance to clarithromycin and fluoroquinolones was performed using the GenoType HelicoDR kit (Hain Lifescience, Nehren, Germany), according to the manufacturer’s instructions. Briefly, the highly specific region, as well as regions of DNA whose mutations lead to resistance to clarithromycin (CLA) and fluoroquinolones (gyrA), were amplified by RT-PCR, using biotin-labelled primers. Amplified products were then denatured and hybridized using specific oligonucleotides (probes) that are complementary to sequences characteristic of wild alleles (WT probes) and sequences of mutated alleles (MUT probes). Reverse hybridization was performed using a TwinCubator at a temperature of 45 °C. A denaturation solution was added to the amplified product (20 μL), after which the remaining steps were performed according to the manufacturer’s protocol (Hain Lifescience, Nehren, Germany) [31].

2.5. Candida spp. Detection

Candida yeasts were detected using the RT-PCR protocol described in a study by Zhang et al. [32]. In short, extracted DNA from gastric biopsy samples was amplified using Mastercycler® ep Gradient S realplex RT-PCR system (Eppendorf) and QuantiNovaTM SYBR® Green PCR Kit (Qiagen). For Candida yeasts detection, the following primers were used: 5.8S-1F5′-CAA CGG ATC TCT TGG TTC TC-3′ and 28S-1R 5′-CGG GTA GTC CTA CCT GAT TT-3′ [32]. Candida species were identified based on the obtained and the reference melting curve profiles. Samples were tested for the presence of several Candida species, including C. albicans, C. tropicalis and C. parapsilosis. For positive controls, C. albicans ATCC24433, C. tropicalis ATCC23705 and C. parapsilosis ATCC24574 were used. Melting curve analysis was performed by gradually increasing the temperature from 65°C to 95 °C at the rate of 1.5 °C/min. The species-specific melting temperatures used for the identification of Candida species are shown in Table 1.
Candida yeasts were detected using the RT-PCR protocol described in a study by Zhang et al. [32]. In short, extracted DNA from gastric biopsy samples was amplified using Mastercycler® ep Gradient S realplex RT-PCR system (Eppendorf) and QuantiNovaTM SYBR® Green PCR Kit (Qiagen). For Candida yeasts detection, the following primers were used: 5.8S-1F5′-CAA CGG ATC TCT TGG TTC TC-3′ and 28S-1R 5′-CGG GTA GTC CTA CCT GAT TT-3′ [32]. Candida species were identified based on the obtained and the reference melting curve profiles. Samples were tested for the presence of several Candida species, including C. albicans, C. tropicalis and C. parapsilosis. For positive controls, C. albicans ATCC24433, C. tropicalis ATCC23705 and C. parapsilosis ATCC24574 were used. Melting curve analysis was performed by gradually increasing the temperature from 65° to 95 °C at the rate of 1.5 °C/min. The species-specific melting temperatures used for the identification of Candida species are shown in Table 1.

2.6. Statistical Analysis

Statistical analyses were performed in order to assess the relationship between Candida colonization, presence of H. pylori gene mutations related to antibiotic resistance and demographic data of patients, as well as the number of eradications and the histopathological scores of biopsies. Non-parametric methods, Chi-square and Fisher’s Exact tests were used for data analysis with a level of significance of p < 0.05. The data were collected and analyzed using SPSS version 26.

3. Results

3.1. Patients Enrolled and Baseline Characteristic

Out of 123 patients in the cohort, biopsy samples of 13 patients were not analyzed in detail due to the negative H. pylori detection results or incomplete information regarding histopathological criteria. For 110 confirmed H. pylori-positive patients, the demographic and clinical data were recorded. The age of participants in the analyzed cohort ranged between 21 and 91 years, with a median age of 56 years. The most reported gastric pathologies included gastritis (n = 74; 67.3%), dyspepsia (n = 19; 17.3%), peptic or duodenal ulcers (n = 11; 10.0%) and gastroesophageal reflux disease (GERD) (n = 11; 10.0%). Gastric biopsies of the participants were investigated, and samples were categorized according to cellularity, inflammatory and atrophy scores.

3.2. Real-Time PCR Detection of Candida Species in DNA Isolated from Gastric Biopsies

Candida species were detected and identified using described real-time PCR method in nine (8.18%) participants (Table 1). At the species level, C. albicans was most frequently detected as it was present in five patients (representing 55.6% of Candida-positive samples), while C. tropicalis and C. parapsilosis were present in two (22.2%) samples each.

3.3. Statistical Assessment of Association between Candida Presence in Gastric Biopsies and Demographic, Clinical and Histological Parameters

Participants were classified into Candida-positive and Candida-negative groups. Statistical analyses were performed by assessing the relationship between the distribution of Candida-positive and Candida-negative patients following different histopathological categories (cellularity levels, inflammatory activity, and observed rate of atrophy), demographic categories (age, gender), number of eradication and the type of antibiotic resistance mutation detected in H. pylori strain (Table 2).
A significantly older age was detected in the Candida-positive group, with a median age of 66 years, compared to a median of 55 years among the Candida-negative patients (p < 0.05). Moreover, all Candida-positive patients were older than 50 years, compared to the Candida-negative group in which 59 participants (58.4%) were >50 years old.
The results of antibiotic resistance testing indicate high resistance rates to both clarithromycin and fluoroquinolone drugs in Candida-positive and Candida-negative groups, with no statistically significant difference between them, as presented in the Table 2 and Figure 1. The most commonly noted mutations included 23S and gyrA mutations, with more than 50% of patients possessing 23S gene mutations in both the Candida-positive (55.6%) and the Candida-negative groups (50.5%).
The statistical analysis revealed absence of a significant association between the presence of Candida species and any of the assessed histopathological categories, number of eradications, gender and the presence of H. pylori mutations (p > 0.05). The cellularity score of 2 was most frequently noted in both groups. Biopsy inflammatory scores of 1 and 2 were the most frequently observed, with the highest rate of inflammatory activity score of 1 in both Candida-positive and Candida-negative groups. Regarding the atrophy assessment, atrophy scores 0 and 1 were most commonly observed, with the majority of patients having an atrophy score of 1, 51% and 66.7% for Candida-negative and Candida-positive patients, respectively (Table 2).
Concerning the pathologies, among Candida-positive participants, the most commonly diagnosed gastrointestinal pathologies included GERD, which was detected in three (33.3%) patients, followed by dyspepsia in two (22.2%), gastroduodenitis in two (22.2%) and gastritis and duodenal ulcer in one patient each (11.1%). Other documented pathologies including sideropenic anemia, esophageal varices and diaphragmatic hernia were absent among Candida-positive patients. The most common diseases diagnosed in the Candida-negative group included gastritis, which was diagnosed in 39 patients, followed by gastroduodenitis diagnosed in 20 patients. Diagnosis of gastritis or duodenitis was more frequent among Candida-negative patients, and this was at the border of significance p = 0.056. Other diagnoses among Candida-negative patients were dyspepsia (17 patients), chronic gastritis (12 patients), duodenal ulcer (9 patients), gastroesophageal reflux (8 patients), hiatus hernia (8 patients), secondary sideropenic anaemia (5 patients) and gastroduodenitis (2 patients). A Chi-square analysis revealed no difference between Candida-positive and negative participants regarding the incidence of ulcers (p> 0.05).

3.4. Statistical Assessment of Association between Detected H. pylori Gene Mutations Associated with Antibiotic Resistance and Demographic, Clinical and Histological Parameters

The presence of gene mutations associated with resistance to fluoroquinolones and clarithromycin was assessed for gyrA, 23S, and gyr87 and gyr91 codon. Overall, the resistance gene mutations to clarithromycin and fluoroquinolone antibiotic classes were found in 57 (52.8%) and 52 (47.3%) samples, respectively (Figure 1).
Correlation analysis revealed a significant association between the resistance to antibiotics and the number of treatments, with a significantly higher incidence of 23S and gyrA mutations observed in previously treated participants, compared to the naïve group (p < 0.05). In particular, significant difference in resistance rates was observed between patients with more than one eradication attempt, compared to the eradication-naïve (naïve) and patients with one episode of eradication, for fluoroquinolone, clarithromycin and dual resistance (p < 0.05). Moreover, higher antibiotics resistance rates were confirmed in patients with failed eradication attempts, for fluoroquinolones (p = 0.008) and clarithromycin (p = 0.002), compared to the naïve group. An overall dual antimicrobial resistance was detected in 33 from 110 (30%) participants. In addition to the higher incidence of detected mutations among participants with recurrent H. pylori infection, significantly higher cellularity, inflammation and atrophy scores were found in previously treated patients compared to the naïve participants (p < 0.05), as shown in Table 3.
Interestingly, resistance to clarithromycin was associated with fluoroquinolone resistance (p = 0.034), as presented in Table 4. Analysis of demographic, clinical and histopathological characteristics in patients separated in groups by their antibiotic resistance status, revealed a significant difference gender-wise, with a higher incidence of clarithromycin-related gene mutations in the female cohort, compared to the male (p = 0.008). Women also had a higher incidence of resistance to both drugs (p = 0.004). There was no significant difference between antibiotic resistance and other parameters, including age, Candida colonization and the presence of gastrointestinal inflammatory diseases (gastritis, duodenitis and ulcers) (p > 0.05).
Significantly higher atrophy scores were observed in patients with resistance to fluoroquinolones (p = 0.001) and dual resistance (p = 0.007), compared to the patients with fluoroquinolone-sensitive H. pylori. No significant difference was observed for the resistance gene mutations and other pathohistological criteria (p > 0.05).

4. Discussion

Considering an increasing prevalence of H. pylori infection, numerous studies have been conducted in order to elucidate factors associated with its eradication. Traditional factors such as patients’ compliance due to therapy duration, as well as potential adverse effects of applied regimen, have been thoroughly evaluated [33]. H. pylori’s resistance represents a major factor in the failure of eradication therapy, and the worldwide increase in the prevalence of resistant strains at an alarming rate has challenged the commonly used triple therapy approach [8,12,34,35]. Although the prevalence of resistant H. pylori strains varies widely across different geographic regions, an association with socioeconomic status has been observed, with higher rates in developing countries [3,36]. A global decrease in the eradication rate has been observed, with <75% of successful treatments commonly reported in the studies [36]. In the majority of developed countries, resistant H. pylori strains to clarithromycin, metronidazole and levofloxacin were assessed to be more than 15%, with clarithromycin resistance the most commonly associated with the treatment failure [37]. The clarithromycin-resistant H. pylori was recently recognized by WHO as a high-priority pathogen for investment in new therapeutics [38,39]. Our alarming data suggested a high resistance to clarithromycin and levofloxacin and further support these studies. Molecular mechanisms behind H. pylori resistance to antibiotics have been intensively researched and point mutations have been identified as the major cause of antibiotics failure [12]. Studies revealed that point mutations in domain V of the 23S rRNA gene and several positions in subunit A of DNA gyrase (gyrA, gyr87, and gyr91) are responsible for H. pylori’s resistance to macrolide and quinolone antibiotics, respectively [8,12,40,41]. The investigation of the common mutations associated with resistance to antibiotics in the present study revealed a significantly higher prevalence of antibiotics resistance genes in subjects who previously had a course of anti-H. pylori antibiotics. The analysis of the correlation between the antibiotic resistance to clarithromycin and fluoroquinolone and the eradication status revealed a significantly higher frequency of mutations related to resistance in previously treated subjects, compared with the untreated group, p < 0.05, as presented in Table 3.
In 2018, the overall prevalence of antibiotic resistance in the European region was estimated to be 32% and 14% for clarithromycin and levofloxacin, respectively. Resistance to clarithromycin has been characterized by high geographical heterogeneity in resistance rates, ranging from 96% in Australia to 15% in Italy [11,42]. In recently published data from the currently largest registered clinical trial regarding H. pylori antimicrobial resistance to take place in the USA and Europe, a comparable and alarmingly high clarithromycin resistance rate was affirmed. Culture based, susceptibility testing revealed that all USA subregions and the majority of European countries have clarithromycin resistance rates above 15% (universally accepted threshold) [14]. Although quinolones had previously been used as an alternative treatment, the rise in H. pylori strains resistant to other antibiotics has increased the usage of levofloxacin and other quinolone drugs. Levofloxacin resistance was estimated to be significantly lower compared to clarithromycin, ranging from 5% in Australia and Italy to 15% in France and 16% in Spain [11]. Worryingly, high resistance rates to both antibiotics were observed in the present study, with 57 (51.8%) and 52 (47.3%) participants colonized with H. pylori resistant to clarithromycin and fluoroquinolones, respectively, showing a significant increase in resistance to antibiotic drugs (Figure 1). Moreover, 33 (30%) subjects had resistance genes to both antibiotic groups which could be partially explained by the large percentage of patients with more than one eradication attempt (75%, Figure 2). Despite the fact that a small cohort of patients was analyzed here, the alarming prevalence of antibiotic-resistant H. pylori strains among Serbian patients requires urgent research and the development of new treatment strategies.
In addition to the primary association of treatment failure with resistance to antibiotics, other factors may further influence the outcome of eradication, including the possible entry of H. pylori inside eukaryotic cells [22]. Intracellular H. pylori has been confirmed in Candida species isolated from oral, gastric and vaginal samples. The internalization of H. pylori inside yeast cells has been proposed to be a possible route of transmission, as the yeast cells are more resistant to the stressful environment [16,20,43,44]. Sanchez-Alonzo and colleagues discovered several driving factors of this endosymbiotic relationship, that trigger the harboring of H. pylori within Candida vacuoles, including temperatures outside the optimal growth range for H. pylori, antibiotics treatment, unfavorable pH conditions [19,23,45]. Results of another study indicate that the harboring of H. pylori within Candida is increased in nutrient-deficient medium and that the endosymbiotic relationship is highly dependent on the H. pylori strain involved [46]. The development of molecular techniques allows researchers an expanded and more accurate insight into the composition of the gastric microbial communities, although very few studies focus on studying fungi and their interrelationship with H. pylori and other members of gastric mucosa remain under-researched [47]. To our knowledge, this is the first study where the presence of Candida yeasts was detected, and Candida species were identified using the culture-independent, RT-PCR method in patients with confirmed H. pylori infection. Previously, Karczewska et al., who studied the co-existence of Candida and H. pylori by using cultivation techniques, reported that 11% of the patients who underwent endoscopy harbored both microorganisms [21]. Similar to the results of cultivation-based study, in our molecular assessment, the presence of both Candida and H. pylori was confirmed in nine patients (8.18%). The most prevalent Candida species was C. albicans found in five Candida-positive patients, followed by C. tropicalis and C. parapsilosis identified in two patients each. Previous studies have identified C. albicans as the most frequently isolated fungus from the gastric mucosa while other Candida species have also been detected, including C. glabrata, C. parapsilosis, C. famata and C. tropicalis [29,48].
The majority of patients in our study had been diagnosed with gastritis or duodenitis (n = 74, 67.3%), which provides further evidence of H. pylori as a causative factor in gastritis development [49]. While Karczewska and colleagues reported a significantly higher incidence of gastric ulcers in the group with H. pylori and Candida co-infection [21], no statistical difference in the incidence of ulcers was found among Candida-positive and negative patients in the current study (p > 0.05). The present results indicate a lower frequency of gastritis or duodenitis in a group with detected Candida colonization at the border of significance (p = 0.056); it should be noted that a relatively small number of Candida-positive samples hampered a reliable statistical assessment. Compared to the study conducted by Zwolińska and colleagues, where fungal colonization was detected in 54.2% of participants with gastric ulcers and 10.3% of chronic gastritis cases, we observed a much lower incidence of gastric ulcers (n = 1; 11%) in Candida-positive patients [29]. GERD was the most frequently diagnosis among Candida-positive patients in our cohort (n = 3; 33%), followed by dyspepsia and gastroduodenitis (n = 2; 22%), representing the variety of gastric pathologies connected with H. pylori colonization [12,50].
Candida-positive patients had a significantly older age (p < 0.05), which further supports previous findings that older age is a major predisposing factor for the fungal colonization of the stomach [51]. According to the current Maastricht guidelines, a high dose of PPI is recommended for H. pylori eradication therapy and all H. pylori-positive patients should be treated with antibiotics [7,45]; meanwhile, it has been shown that in addition to the older age, treatment with PPIs also favors Candida colonization of the gastric mucosa [51]. Besides representing part of the therapy regimens for H. pylori eradication, PPIs are widely prescribed drugs for other indications. However, recent studies have proved that chronic PPI usage promotes perturbations in gastric microbial communities by altering the pH value in the stomach [48,52]. A connection between PPI usage and fungal colonization of the stomach has been also confirmed in a study by Mottaghi and colleagues, where the use of ranitidine, pantoprazole and omeprazole was associated with a significantly increased risk of gastric candidiasis [31].
Previous studies indicated a connection between H. pylori infection and intestinal microbiota dysbiosis [25]. The alterations in the fungal gastrointestinal community, characterized by an increased abundance of Candida glabrata and other unclassified fungi, were also found to be associated with H. pylori infection [53]. In addition to the direct impact that H. pylori on gastric microbial communities, attempts at H. pylori eradication using several courses of antibiotics also affect the gastric microbiota and may result in gastric dysbiosis [54,55]. In this analysis’ cohort, all patients were H. pylori positive. We found no significant difference in resistance rates between Candida-positive and Candida-negative groups, indicating that yeast colonization alone does not have a major impact on the transmission of H. pylori resistance genes.
In addition to the endosymbiotic relationship, other forms of interactions between fungal and bacterial gastric community members have been observed, including the adherence of H. pylori to Candida species and the development of polymicrobial biofilms [56,57]. However, it is still not clear whether the co-infection of Candida and H. pylori exacerbates the development of gastric diseases. The results of recent studies indicate the importance of other gastric microbial members in the pathogenesis of gastric inflammatory diseases. Notably, the existence of a significant correlation between gastric dysbiosis and aforementioned pathologies was observed, highlighting the importance of perturbations in the gastric microbiome in the etiopathology of gastric diseases [24,27,28,53]. Moreover, an association between dysbiosis of the fungal gastric community and the development of gastritis, ulcers and gastric cancer has been also proven in several studies, indicating the significance of microbiota dysbiosis [47,58,59].
In order to combat a growing global antibiotic resistance and prevalence of H. pylori infection, a more responsible antibiotic stewardship should be implemented. Tailored therapy based on individual susceptibility testing has been proved to be more effective than empiric therapy (especially in high clarithromycin resistance regions) [14]. Although regular testing for resistance genes has not been recommended by the last Maastricht guideline, awareness of the strain-specific genetic structure could improve treatment effectiveness, i.e., help to tailor therapy that would reduce the number of eradication attempts, to the benefits of patients and healthcare providers. [7]. Assessing antibiotic susceptibility prior to eradication therapy is a relatively novel therapeutic approach that allows for an individualization of therapy. However, studies have shown that the H. pylori-antibiotics interrelationship is more intricate and tailored therapy does not always lead to eradication [60]. This could be, potentially, attributed to Candida colonization which would enable resistance to an antibiotic susceptible H. pylori strain, by allowing it intracellular protection, leading to treatment failure. Latifi-Navid et al. and our unpublished data reveal ketoconazole as an agent which can additionally lead to successful eradication and can reduce the chance of recurrence of bacterial infection. However, further studies are warranted to elucidate the extent of their relationship [61].

5. Conclusions

In this study, antibiotic resistance genes and colonization with Candida yeast was assessed in a small cohort of H. pylori-positive patients, with an idea to elucidate reasons for H. pylori eradication failure. While there is an alarming level of antibiotic resistance (52% and 47% of participants possessed genes related to clarithromycin and fluoroquinolone resistance, respectively), the co-occurrence of H. pylori and Candida species were found in only 8% of patients. In the analyzed cohort, the fungal colonization was associated with older age, suggesting that the age-related changes in physiological functions and microbiome composition favors Candida colonization of the stomach. Previous studies suggested that Candida could serve as a host facilitating a rescue of H. pylori under unfavorable conditions. Our results suggest that such phenomena could exist only in a small proportion of patients. A global increase in the prevalence of resistant H. pylori strains has resulted in an increased interest in H. pylori infection management strategies. New approaches, including vaccines, phytochemicals, secondary bacterial metabolites and probiotic strains are needed. Moreover, as studies of the mechanisms of H. pylori invasiveness and colonization revealed the facultative intracellular nature of bacteria, further research into the endosymbiotic relationship between H. pylori and Candida species is suggested.

Author Contributions

A.B. and V.M. contributed equally to the work. Conceptualization, V.M. and A.B.; methodology, V.M., D.K., I.G. and M.R.-S.; investigation, V.M. and A.B.; data analysis, B.M.B.; writing—original draft preparation, V.M. and A.B.; writing—review and editing D.P., T.M. and M.R.-S.; visualization, I.P., D.K. and B.M.B.; supervision, T.M. and M.R.-S. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the Ministry of Education, Science and Technological Development of the Republic of Serbia (Contract No. 451-03-9/2021-14/200287, 451-03-9/2021-14/200135, 451-03-68/2022-14/200135, 451-03-68/2022-14/200110) 175039.

Institutional Review Board Statement

The study was approved by the Ethics Committee of the University Clinical Centre of Serbia (number 788/11).

Informed Consent Statement

All patients were informed regarding the aim of the study and provided written informed consent in accordance with the World Medical Association Declaration of Helsinki.

Data Availability Statement

Data regarding investigated patents and statistical analysis will not be made publicly available.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Kotilea, K.; Bontems, P.; Touati, E. Epidemiology, Diagnosis and Risk Factors of Helicobacter pylori Infection. In Helicobacter pylori in Human Diseases: Advances in Microbiology, Infectious Diseases and Public Health; Kamiya, S., Backert, S., Eds.; Springer: Cham, Switzerland, 2019; Volume 11, pp. 17–33. [Google Scholar]
  2. Marcus, E.A.; Scott, D.R. Gastric Colonization by H. pylori. In Helicobacter pylori; Kim, N., Ed.; Springer: Singapore, 2016; pp. 23–34. [Google Scholar]
  3. Sjomina, O.; Pavlova, J.; Niv, Y.; Leja, M. Epidemiology of Helicobacter pylori infection. Helicobacter 2018, 23 (Suppl. S1), e12514. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Zamani, M.; Ebrahimtabar, F.; Zamani, V.; Miller, W.H.; Alizadeh-Navaei, R.; Shokri-Shirvani, J.; Derakhshan, M.H. Systematic review with meta-analysis: The worldwide prevalence of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 2018, 47, 868–876. [Google Scholar] [CrossRef] [Green Version]
  5. Marshall, B.J.; Warren, J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984, 1, 1311–1315. [Google Scholar] [CrossRef] [PubMed]
  6. Moss, S.F. The Clinical Evidence Linking Helicobacter pylori to Gastric Cancer. Cell Mol. Gastroenterol. Hepatol. 2017, 3, 183–191. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Malfertheiner, P.; Megraud, F.; Rokkas, T.; Gisbert, J.P.; Liou, J.M.; Schulz, C.; Gasbarrini, A.; Hunt, R.H.; Leja, M.; O’Morain, C.; et al. Management of Helicobacter pylori infection: The Maastricht VI/Florence consensus report. Gut 2022, 71, 1724–1762. [Google Scholar] [CrossRef] [PubMed]
  8. Francesco, V.D.; Zullo, A.; Hassan, C.; Giorgio, F.; Rosania, R.; Ierardi, E. Mechanisms of Helicobacter pylori Antibiotic Resistance: An updated appraisal. World J. Gastrointest. Pathophysiol. 2011, 2, 35–41. [Google Scholar] [CrossRef]
  9. Nyssen, O.P.; Bordin, D.; Tepes, B.; Pérez-Aisa, Á.; Vaira, D.; Caldas, M.; Bujanda, L.; Castro-Fernandez, M.; Lerang, F.; Leja, M.; et al. European Registry on Helicobacter pylori management (Hp-EuReg): Patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut 2021, 70, 40–54. [Google Scholar] [CrossRef]
  10. Nyssen, O.P.; Vaira, D.; Pérez-Aísa, Á.; Rodrigo, L.; Castro-Fernandez, M.; Jonaitis, L.; Tepes, B.; Vologzhanina, L.; Caldas, M.; Lanas, A.; et al. Empirical second-line therapy in 5000 patients of the European registry on Helicobacter pylori management (Hp-EuReg). Clin. Gastroenterol. Hepatol. 2022, 20, 2243–2257. [Google Scholar] [CrossRef]
  11. Savoldi, A.; Carrara, E.; Graham, D.Y.; Conti, M.; Tacconelli, E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology 2018, 155, 1372–1382.e17. [Google Scholar] [CrossRef] [Green Version]
  12. Tshibangu-Kabamba, E.; Yamaoka, Y. Helicobacter pylori infection and antibiotic resistance—From biology to clinical implications. Nat. Rev. Gastroenterol. Hepatol. 2021, 18, 613–629. [Google Scholar] [CrossRef]
  13. Boyanova, L.; Hadzhiyski, P.; Kandilarov, N.; Markovska, R.; Mitov, I. Multidrug resistance in Helicobacter pylori: Current state and future directions. Expert Rev. Clin. Pharmacol. 2019, 12, 909–915. [Google Scholar] [CrossRef] [PubMed]
  14. Mégraud, F.; Graham, D.Y.; Howden, C.W.; Trevino, E.; Weissfeld, A.; Hunt, B.; Smith, N.; Leifke, E.; Chey, W.D. Rates of Antimicrobial Resistance in Helicobacter pylori Isolates from Clinical Trial Patients Across the US and Europe. Am. J. Gastroenterol. 2022, 118, 269–275. [Google Scholar] [CrossRef] [PubMed]
  15. Morino, Y.; Sugimoto, M.; Nagata, N.; Niikiura, R.; Iwata, E.; Hamada, M.; Kawai, Y.; Fujimiya, T.; Takeuchi, H.; Unezaki, S.; et al. Influence of Cytochrome P450 2C19 Genotype on Helicobacter pylori Proton Pump Inhibitor-Amoxicillin-Clarithromycin Eradication Therapy: A Meta-Analysis. Front. Pharmacol. 2021, 12, 759249. [Google Scholar] [CrossRef] [PubMed]
  16. Hou, C.; Yin, F.; Wang, S.; Zhao, A.; Li, Y.; Liu, Y. Helicobacter pylori Biofilm-Related Drug Resistance and New Developments in Its Anti-Biofilm Agents. Infect. Drug Resist. 2022, 15, 1561–1571. [Google Scholar] [CrossRef] [PubMed]
  17. Campos, P.L.; Merino-Barrera, J.S.; Smith, C.T.; García-Cancino, A. Candida sp. as a potential reservoir and transmission facilitator of Helicobacter pylori. Biomed. J. Sci. Tech. Res. 2018, 4, 3736–3738. [Google Scholar]
  18. Siavoshi, F.; Saniee, P. Vacuoles of Candida yeast as a specialized niche for Helicobacter pylori. World J. Gastroenterol. 2014, 20, 5263–5273. [Google Scholar] [CrossRef]
  19. Sánchez-Alonzo, K.; Arellano-Arriagada, L.; Castro-Seriche, S.; Parra-Sepúlveda, C.; Bernasconi, H.; Benavidez-Hernández, H.; Campos, V.L.; Sáez, K.; Smith, C.T.; García-Cancino, A. Temperatures Outside the Optimal Range for Helicobacter pylori Increase Its Harboring within Candida Yeast Cells. Biology 2021, 10, 915. [Google Scholar] [CrossRef]
  20. Saniee, P.; Siavoshi, F.; Nikbakht-Broujeni, G.; Khormali, M.; Sarrafnejad, A.; Malekzadeh, R. Localization of H. pylori within the vacuole of Candida yeast by direct immunofluorescence technique. Arch. Iran Med. 2013, 16, 705–710. [Google Scholar]
  21. Karczewska, E.; Wojtas, I.; Sito, E.; Trojanowska, D.; Budak, A.; Zwolinska-Wcislo, M.; Wilk, A. Assessment of co-existence of Helicobacter pylori and Candida fungi in diseases of the upper gastrointestinal tract. J. Physiol. Pharmacol. 2009, 60 (Suppl. S6), 33–39. [Google Scholar]
  22. Mason, K.L.; Erb-Downward, J.R.; Falkowski, N.R.; Young, V.B.; Kao, J.Y.; Huffnagle, G.B. Interplay between the gastric bacterial microbiota and Candida albicans during postantibiotic recolonization and gastritis. Infect. Immun. 2012, 80, 150–158. [Google Scholar] [CrossRef] [Green Version]
  23. Sánchez-Alonzo, K.; Belmar, L.; Parra-Sepúlveda, C.; Bernasconi, H.; Campos, V.L.; Smith, C.T.; Sáez, K.; García-Cancino, A. Antibiotics as a Stressing Factor Triggering the Harboring of Helicobacter pylori J99 within Candida albicans ATCC10231. Pathogens 2021, 10, 382. [Google Scholar] [CrossRef] [PubMed]
  24. Duan, X.; Chen, P.; Xu, X.; Han, M.; Li, J. Role of Gastric Microorganisms Other than Helicobacter pylori in the Development and Treatment of Gastric Diseases. BioMed Res. Int. 2022, 2022, 6263423. [Google Scholar] [CrossRef]
  25. Rajilic-Stojanovic, M.; Figueiredo, C.; Smet, A.; Hansen, R.; Kupcinskas, J.; Rokkas, T.; Andersen, L.; Machado, J.C.; Ianiro, G.; Gasbarrini, A.; et al. Systematic review: Gastric microbiota in health and disease. Aliment. Pharmacol. Ther. 2020, 51, 582–602. [Google Scholar] [CrossRef]
  26. Nardone, G.; Compare, D. The human gastric microbiota: Is it time to rethink the pathogenesis of stomach diseases? United Eur. Gastroenterol. J. 2015, 3, 255–260. [Google Scholar] [CrossRef] [Green Version]
  27. Hansen, A.; Johannesen, T.B.; Spiegelhauer, M.R.; Kupcinskas, J.; Urba, M.; Skieceviciene, J.; Jonaitis, L.; Frandsen, T.H.; Kupcinskas, L.; Fuursted, K.; et al. Distinct composition and distribution of the gastric mycobiota observed between dyspeptic and gastric cancer patients evaluated from gastric biopsies. Microb. Heal. Dis. 2020, 2, 340–355. [Google Scholar]
  28. Ianiro, G.; Molina-Infante, J.; Gasbarrini, A. Gastric Microbiota. Helicobacter 2015, 20 (Suppl. S1), 68–71. [Google Scholar] [CrossRef] [Green Version]
  29. Zwolinska-Wcisło, M.; Budak, A.; Bogdał, J.; Trojanowska, D.; Stachura, J. Fungal colonization of gastric mucosa and its clinical relevance. Med. Sci. Monit. 2001, 7, 982–988. [Google Scholar] [PubMed]
  30. Dixon, M.F.; Genta, R.M.; Yardley, J.H.; Correa, P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am. J. Surg. Pathol. 1996, 20, 1161–1181. [Google Scholar] [CrossRef] [PubMed]
  31. Guimarães, N.; Azevedo, N.F.; Figueiredo, C.; Keevil, C.W.; Vieira, M.J. Development and application of a novel peptide nucleic acid probe for the specific detection of Helicobacter pylori in gastric biopsy specimens. J. Clin. Microbiol. 2007, 45, 3089–3094. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Zhang, J.; Hung, G.C.; Nagamine, K.; Li, B.; Tsai, S.; Lo, S.C. Development of Candida-Specific Real-Time PCR Assays for the Detection and Identification of Eight Medically Important Candida Species. Microbiol. Insights 2016, 9, 21–28. [Google Scholar] [CrossRef] [Green Version]
  33. Lü, M.; Yu, S.; Deng, J.; Yan, Q.; Yang, C.; Xia, G.; Zhou, X. Efficacy of probiotic supplementation therapy for Helicobacter pylori eradication: A meta-analysis of randomized controlled trials. PLoS ONE 2016, 11, e0163743. [Google Scholar] [CrossRef] [Green Version]
  34. Thung, I.; Aramin, H.; Vavinskaya, V.; Gupta, S.; Park, J.Y.; Crowe, S.E.; Valasek, M.A. Review article: The global emergence of Helicobacter pylori antibiotic resistance. Aliment. Pharmacol. Ther. 2016, 43, 514–533. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Zou, Y.; Qian, X.; Liu, X.; Song, Y.; Song, C.; Wu, S.; An, Y.; Yuan, R.; Wang, Y.; Xie, Y. The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: A systematic review and meta-analysis. Helicobacter 2020, 25, e12714. [Google Scholar] [CrossRef] [PubMed]
  36. Jaka, H.; Rhee, J.A.; Östlundh, L.; Smart, L.; Peck, R.; Mueller, A.; Kasang, C.; Mshana, S.E. The magnitude of antibiotic resistance to Helicobacter pylori in Africa and identified mutations which confer resistance to antibiotics: Systematic review and meta-analysis. BMC Infect. Dis. 2018, 18, 193. [Google Scholar] [CrossRef] [PubMed]
  37. Perna, F.; Zullo, A.; Ricci, C.; Hassan, C.; Morini, S.; Vaira, D. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: Role of bacterial resistance. Dig. Liver Dis. 2007, 39, 1001–1005. [Google Scholar] [CrossRef] [PubMed]
  38. Tacconelli, E.; Carrara, E.; Savoldi, A.; Harbarth, S.; Mendelson, M.; Monnet, D.L.; Pulcini, C.; Kahlmeter, G.; Kluytmans, J.; Carmeli, Y.; et al. Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 2018, 18, 318–327. [Google Scholar] [CrossRef] [PubMed]
  39. Sasaki, K. Candida-associated gastric ulcer relapsing in a different position with a different appearance. World J. Gastroenterol. 2012, 18, 4450–4453. [Google Scholar] [CrossRef]
  40. Marques, A.T.; Vítor, J.M.B.; Santos, A.; Oleastro, M.; Vale, F.F. Trends in Helicobacter pylori resistance to clarithromycin: From phenotypic to genomic approaches. Microb. Genom. 2020, 6, 344–355. [Google Scholar]
  41. Talarico, S.; Korson, A.S.; Leverich, C.K.; Park, S.; Jalikis, F.G.; Upton, M.P.; Broussard, E.; Salama, N.R. High prevalence of Helicobacter pylori clarithromycin resistance mutations among Seattle patients measured by droplet digital PCR. Helicobacter 2018, 23, e12472. [Google Scholar] [CrossRef]
  42. Ghotaslou, R.; Leylabadlo, H.E.; Asl, Y.M. Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review. World J. Methodol. 2015, 5, 164–174. [Google Scholar] [CrossRef]
  43. Sánchez-Alonzo, K.; Matamala-Valdés, L.; Parra-Sepúlveda, C.; Bernasconi, H.; Campos, V.L.; Smith, C.T.; Sáez, K.; García-Cancino, A. Intracellular Presence of Helicobacter pylori and Its Virulence-Associated Genotypes within the Vaginal Yeast of Term Pregnant Women. Microorganisms 2021, 9, 131. [Google Scholar] [CrossRef]
  44. Sánchez-Alonzo, K.; Parra-Sepúlveda, C.; Vergara, L.; Bernasconi, H.; García-Cancino, A. Detection of Helicobacter pylori in oral yeasts from students of a Chilean university. Rev. Assoc. Med. Bras. 2020, 66, 1509–1514. [Google Scholar] [CrossRef]
  45. Sánchez-Alonzo, K.; Parra-Sepúlveda, C.; Vega, S.; Bernasconi, H.; Campos, V.L.; Smith, C.T.; Sáez, K.; García-Cancino, A. In vitro incorporation of Helicobacter pylori into Candida albicans caused by acidic pH stress. Pathogens 2020, 9, 489. [Google Scholar] [CrossRef]
  46. Sánchez-Alonzo, K.; Silva-Mieres, F.; Arellano-Arriagada, L.; Parra-Sepúlveda, C.; Bernasconi, H.; Smith, C.T.; Campos, V.L.; García-Cancino, A. Nutrient Deficiency Promotes the Entry of Helicobacter pylori Cells into Candida Yeast Cells. Biology 2021, 10, 426. [Google Scholar] [CrossRef] [PubMed]
  47. Wang, Z.; Ren, R.; Yang, Y. Mucosa microbiome of gastric lesions: Fungi and bacteria interactions. Prog. Mol. Biol. Transl. Sci. 2020, 171, 195–213. [Google Scholar] [PubMed]
  48. Mottaghi, B.; Emami, M.H.; Riahi, P.; Fahim, A.; Rahimi, H.; Mohammadi, R. Candida colonization of the esophagus and gastric mucosa; a comparison of patients taking proton pump inhibitors and those taking histamine receptor antagonist drugs. Gastroenterol. Hepatol. Bed Bench 2021, 14, 349–355. [Google Scholar]
  49. Sugano, K.; Tack, J.; Kuipers, E.J.; Graham, D.Y.; El-Omar, E.M.; Miura, S.; Haruma, K.; Asaka, M.; Uemura, N.; Malfertheiner, P. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015, 64, 1353–1367. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  50. Tham, K.T.; Peek, R.M., Jr.; Atherton, J.C.; Cover, T.L.; Perez-Perez, G.I.; Shyr, Y.; Blaser, M.J. Helicobacter pylori genotypes, host factors, and gastric mucosal histopathology in peptic ulcer disease. Hum. Pathol. 2001, 32, 264–273. [Google Scholar] [CrossRef]
  51. Massarrat, S.; Saniee, P.; Siavoshi, F.; Mokhtari, R.; Mansour-Ghanaei, F.; Khalili-Samani, S. The Effect of Helicobacter pylori Infection, Aging, and Consumption of Proton Pump Inhibitor on Fungal Colonization in the Stomach of Dyspeptic Patients. Front. Microbiol. 2016, 7, 801. [Google Scholar] [CrossRef]
  52. Ierardi, E.; Losurdo, G.; Fortezza, R.F.; Principi, M.; Barone, M.; Leo, A.D. Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness. World J. Gastroenterol. 2019, 25, 5097–5104. [Google Scholar] [CrossRef]
  53. Dash, N.R.; Khoder, G.; Nada, A.M.; Al Bataineh, M.T. Exploring the impact of Helicobacter pylori on gut microbiome composition. PLoS ONE 2019, 14, e0218274. [Google Scholar] [CrossRef] [Green Version]
  54. Ianiro, G.; Tilg, H.; Gasbarrini, A. Antibiotics as deep modulators of gut microbiota: Between good and evil. Gut 2016, 65, 1906–1915. [Google Scholar] [CrossRef] [Green Version]
  55. Chen, C.-C.; Liou, J.M.; Lee, Y.C.; Hong, T.C.; El-Omar, E.M.; Wu, M.S. The interplay between Helicobacter pylori and gastrointestinal microbiota. Gut Microbes 2021, 13, 1909459. [Google Scholar] [CrossRef] [PubMed]
  56. Ansorg, R.; Schmid, E.N. Adhesion of Helicobacter pylori to yeast cells. Zent. Für Bakteriol. 1998, 288, 501–508. [Google Scholar] [CrossRef]
  57. Palencia, S.L.; García, A.; Palencia, M. Multiple surface interaction mechanisms direct the anchoring, co-aggregation and formation of dual-species biofilm between Candida albicans and Helicobacter pylori. J. Adv. Res. 2022, 35, 169–185. [Google Scholar] [CrossRef] [PubMed]
  58. Yang, P.; Zhang, X.; Xu, R.; Adeel, K.; Lu, X.; Chen, M.; Shen, H.; Li, Z.; Xu, Z. Fungal Microbiota Dysbiosis and Ecological Alterations in Gastric Cancer. Front. Microbiol. 2022, 13, 1367–1380. [Google Scholar] [CrossRef]
  59. Papon, N.; Hohl, T.M.; Zhai, B. Mycobiota dysbiosis and gastric tumorigenesis. Theranostics 2021, 11, 7488–7490. [Google Scholar] [CrossRef]
  60. Gisbert, J.P. Empirical or susceptibility-guided treatment for Helicobacter pylori infection? A comprehensive review. Ther. Adv. Gastroenterol. 2020, 13, 1756284820968736. [Google Scholar] [CrossRef] [PubMed]
  61. Latifi-Navid, S.; Siavoshi, F.; Safari, F.; Malekzadeh, R.; Massarrat, S. Antimicrobial effectiveness of ketoconazole against metronidazole-resistant Helicobacter pylori isolates from Iranian dyspeptic patients. J. Antimicrob. Chemother. 2006, 59, 160–161. [Google Scholar] [CrossRef]
Jof 09 00328 g001 550
Figure 1. Overall resistance rates to fluoroquinolones and clarithromycin detected by PCR and antibiotic resistance rates in Candida-negative and Candida- positive groups (a–f).
Figure 1. Overall resistance rates to fluoroquinolones and clarithromycin detected by PCR and antibiotic resistance rates in Candida-negative and Candida- positive groups (a–f).
Jof 09 00328 g001
Jof 09 00328 g002 550
Figure 2. (a) Distribution of patients in the cohort according to the number of H. pylori eradication attempts (n, %); (b) Distribution of cellularity, inflammatory activity, and atrophy scores among patients in the cohort.
Figure 2. (a) Distribution of patients in the cohort according to the number of H. pylori eradication attempts (n, %); (b) Distribution of cellularity, inflammatory activity, and atrophy scores among patients in the cohort.
Jof 09 00328 g002
Table
Table 1. Temperatures used for Candida species identification and number of identified Candida species.
Table 1. Temperatures used for Candida species identification and number of identified Candida species.
Melting Curves Temperatures Used for Candida Identification (°C)Candida SpeciesNumber of Candida–Positive Patients
n, (%)
87.2/87.7C. albicans5 (55.6%)
84.7C. tropicalis2 (22.2%)
85.3C. parapsilosis2 (22.2%)
Table
Table 2. Overview of characteristics in Candida-negative and Candida-positive patients.
Table 2. Overview of characteristics in Candida-negative and Candida-positive patients.
CategoriesCandida–Negative Group n, (%)Candida–Positive Group n, (%)p Value
Number of participants101 (91.82%)9 (8.18%)
Median age (years)5566
<4020 (19.80%)00.208
40–50 22 (21.80%)0
>5059 (58.40%)9 (100%)0.012 *
Gender0.152
Male39 (38.60%)6 (66.70%)
Female62 (61.40%)3 (33.30%)
Number of eradications
Naïve27 (26.70%)1 (11.1%)0.443
>= 1 eradications74, (73.3%)8 (88.9%)
>=2 eradications55, (54.5%)6 (66.7%)0.729
Resistance to antibiotics
Fluoroquinolone (FLQ)50 (49.5%)2 (22.2%)0.167
Clarithromycin (CLA)52 (51.5%)5 (55.6%)1
Dual Resistance (FLQ-R and CLA-R)32 (31.7%)1 (11.1%)0.274
FLQ-S and CLA-S 31 (30.7%)3 (33.3%)1
FLQ-R or CLA-R 70 (69.3%)6 (66.7%)0.184
Mutations
gyrA MUT41 (40.6%)1 (11.1%)0.149
23S MUT51 (50.5%)5 (55.6%)1
gyr87 MUT16 (15.8%)00.352
gyr91 MUT20 (19.8%)1 (11.1%)1
Histopathological categories
Cellularity score 0.812
01 (1.0%)/
136 (36.0%)3 (33.0%)
259 (59.0%)6 (67.0%)
34 (4.0%)/
Inflammatory activity 0.554
08 (8.0%)/
150 (50.0%)6 (66.7%)
241 (41.0%)3 (33.3%)
31 (1.0%)/
Atrophy score 0.601
041 (41.0%)3 (33.3%)
151 (51.0%)6 (66.7%)
27 (7.0%)/
31 (1.0%)/
* p < 0.05 significance level.
Table
Table 3. Overview of characteristics in naïve and previously eradicated patients.
Table 3. Overview of characteristics in naïve and previously eradicated patients.
CategoriesTotalTreatment Statusp Value
NaïvePreviously Treated
n, (%)nn
Fluoroquinolone (FLQ) resistance52 (47.3%)7450.008 *
Clarithromycin (CLA) resistance57 (52.8%)7500.002 *
Dual Resistance (FLQ-R and CLA-R)33 (30%)4290.054
Mutations
23S mutation56 (50.9%)7490.002 *
gyr 91 mutation21 (19.1%)3180.268
gyrA mutation42 (38.2%)5370.013 *
gyr 87 mutation16 (14.5%)3130.757
Histopathological scores
Atrophy score 0.018 *
0441826
157849
2725
3101
Cellularity score 0.018 *
0110
1391524
2651253
3404
Inflammatory activity 0.002 *
0853
1561739
244638
3101
*p < 0.05 significance level.
Table
Table 4. Results of Chi-square analysis of characteristics between antibiotic resistant and sensitive groups.
Table 4. Results of Chi-square analysis of characteristics between antibiotic resistant and sensitive groups.
CategoriesFLQ Resistance (p Value)CLA Resistance (p Value)Dual Resistance (p Value)
>40 years old0.63610.787
>50 years old0.8890.9180.638
Gender0.0940.008 *0.004 *
Candida status0.2220.8150.362
Number of eradication0.001 *0.003 *0.001 *
Naïve vs Repeated Eradication0.012 *0.001 *0.062
Naïve and 1 vs. >1 eradication0.001 *0.001 *0.001 *
Celularity score0.9070.3330.453
Celularity score 0 and 1 vs. >10.6280.2460.259
Inflammatory activity0.3360.730.242
Inflammatory activity 0 and 1 vs. >10.340.0530.223
Atrophy score0.001 *0.0970.007 *
Atrophy score 0 vs. >00.017 *0.0780.013 *
Gastritis/Duodenitis0.8330.6390.562
Ulcers0.2950.4620.237
Fluoroquinolone (FLQ) Resistance 0.034 *
* p < 0.05 significance level.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Bačić, A.; Milivojević, V.; Petković, I.; Kekić, D.; Gajić, I.; Medić Brkić, B.; Popadić, D.; Milosavljević, T.; Rajilić-Stojanović, M. In Search for Reasons behind Helicobacter pylori Eradication Failure–Assessment of the Antibiotics Resistance Rate and Co-Existence of Helicobacter pylori with Candida Species. J. Fungi 2023, 9, 328. https://doi.org/10.3390/jof9030328

AMA Style

Bačić A, Milivojević V, Petković I, Kekić D, Gajić I, Medić Brkić B, Popadić D, Milosavljević T, Rajilić-Stojanović M. In Search for Reasons behind Helicobacter pylori Eradication Failure–Assessment of the Antibiotics Resistance Rate and Co-Existence of Helicobacter pylori with Candida Species. Journal of Fungi. 2023; 9(3):328. https://doi.org/10.3390/jof9030328

Chicago/Turabian Style

Bačić, Ana, Vladimir Milivojević, Isidora Petković, Dušan Kekić, Ina Gajić, Branislava Medić Brkić, Dušan Popadić, Tomica Milosavljević, and Mirjana Rajilić-Stojanović. 2023. "In Search for Reasons behind Helicobacter pylori Eradication Failure–Assessment of the Antibiotics Resistance Rate and Co-Existence of Helicobacter pylori with Candida Species" Journal of Fungi 9, no. 3: 328. https://doi.org/10.3390/jof9030328

APA Style

Bačić, A., Milivojević, V., Petković, I., Kekić, D., Gajić, I., Medić Brkić, B., Popadić, D., Milosavljević, T., & Rajilić-Stojanović, M. (2023). In Search for Reasons behind Helicobacter pylori Eradication Failure–Assessment of the Antibiotics Resistance Rate and Co-Existence of Helicobacter pylori with Candida Species. Journal of Fungi, 9(3), 328. https://doi.org/10.3390/jof9030328

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop